NDA 215727 · Agepha Pharma Fz
Lodoco
Colchicine · Oral · Alkaloid
Priority reviewLast checked: Nov 19, 2026Latest source record: Jun 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jun 16, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
313
94 Phase 3, 51 recruiting
FAERS reports
24
8 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 20, 2026.
1. INDICATION AND USAGE LODOCO is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. LODOCO is an alkaloid indicated: • to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease ( 1 ).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 16, 2023 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LetterLabelReview
1 products under this application
- LODOCO · COLCHICINE 0.5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Colchicine" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- ACT-GLOBAL Adaptive Platform Trial for StrokePivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06352632 · 20,000 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 2034
Drug: Standard-dose intravenous tenecteplase; Low-dose intravenous tenecteplase and 9 more · For: Stroke
Sites: Sydney, Australia; Calgary, Canada
- COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 DiabetesPivotal-lookingRecruiting
Montreal Heart InstituteAcademic, hospital or other
NCT05633810 · 10,000 participants (planned) · Start Dec 21, 2022 · Primary completion Dec 2027
Drug: Aspirin; Aspirin Placebo and 2 more · For: Diabete Type 2; Cardiovascular Diseases
Sites: Bentley, Australia; Toronto, Canada; Montreal, Canada · 39 sites in all
- Efficacy and Safety of Colchicine After PCIPivotal-lookingActive, not recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT06472908 · 8,862 participants (planned) · Start Jul 9, 2024 · Primary completion Jun 30, 2027
Drug: Colchicine 0.5 mg; Colchicine 0.375 mg and 1 more · For: Coronary Heart Disease; Percutaneous Coronary Intervention; Colchicine
Sites: Hefei, China; Beijing, China; Chongqing, China · 36 sites in all
- Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)Pivotal-lookingCompleted
Beijing Tiantan HospitalAcademic, hospital or other
NCT05439356 · 8,343 participants · Start Aug 11, 2022 · Primary completion Jul 13, 2023
Drug: Colchicine; Placebo colchicine · For: Ischemic Stroke; TIA
Sites: Fuyang, China; Huangshan City, China; Wuhu, China · 244 sites in all
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular DiseasePivotal-lookingRecruiting
Hospital do CoracaoAcademic, hospital or other
NCT06930885 · 7,713 participants (planned) · Start Jun 12, 2025 · Primary completion May 2031
Drug: Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin); Colchicine 0.5 mg and 2 more · For: Atherothrombotic Diseases; Atherosclerotic Cardiovascular Disease (ASCVD)
Sites: Maceió, Brazil; Messejana, Brazil; Petrolina, Brazil · 13 sites in all
- Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)Pivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07035405 · 7,500 participants (planned) · Start Jul 4, 2025 · Primary completion Dec 31, 2028
Drug: Colchicine 0.5 mg; Placebo colchicine · For: Stroke
- Colchicine and Spironolactone in Patients with MI / SYNERGY Stent RegistryPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03048825 · 7,264 participants · Start Feb 1, 2018 · Primary completion Aug 9, 2024
Drug: Colchicine; Spironolactone and 2 more · For: ST Elevation Myocardial Infarction; Non ST Elevation Myocardial Infarction
Sites: Bakersfield, California; Washington D.C., District of Columbia; Chicago, Illinois · 109 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea4
- abdominal discomfort3
- pain3
- dizziness2
- fatigue2
- nausea2
- product use in unapproved indication2
- product use issue2
- abdominal pain1
- abdominal pain upper1
- adverse event1
- back pain1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lodoco (Colchicine)
2024 spending
$606K
Beneficiaries
294
723 claims
Per beneficiary
$2,060
$15.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $45,668 |
| 2024 | $605,582 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Tardif JC, Kouz S, Waters DD, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Colchicine in Acute Myocardial Infarction.
Jolly SS, d'Entremont MA, Lee SF, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Colchicine in Patients with Chronic Coronary Disease.
Nidorf SM, Fiolet ATL, Mosterd A, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
Bouabdallaoui N, Tardif JC, Waters DD, et al. · Eur Heart J 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis.
Samuel M, Berry C, Dubé MP, et al. · Eur Heart J 2025 · Meta-Analysis, Systematic Review
- Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
De Benedetti F, Gattorno M, Anton J, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Agepha Pharma Fz
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.